CGON Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
["Not a good buy right now for an impatient trader: momentum is weakening (MACD negative and expanding), and the stock is sitting just below the key pivot/resistance area (~54.47).", "Options positioning is bullish (call-heavy put/call ratios), but implied volatility is high, implying the market is already pricing in big moves\u2014risk/reward for a new chase entry is less attractive.", "Heavy insider selling (up ~1311% over the last month) is a material near-term negative signal that can cap upside even with supportive analyst sentiment."]
["Trend/momentum: MACD histogram -0.47 and negatively expanding => bearish momentum building despite the broader uptrend in averages.", "Moving averages: SMA_5 > SMA_20 > SMA_200 => structure remains bullish, suggesting this is more of a pullback/hesitation within a longer uptrend.", "RSI_6 at 46.3 => neutral; no oversold bounce signal yet.", "Key levels: Pre-market ~53.84 is below Pivot 54.467 (near-term ceiling). First support S1 51.984, then S2 50.45; resistances R1 56.95 and R2 58.484.", "Intellectia Proprietary Trading Signals\n- AI Stock Picker: No signal on given stock today.\n- SwingMax: No signal on given stock recently."]
["Clinical/regulatory timeline catalysts: Updated PIVOT-006 topline data now expected in 1H26; rolling BLA submission underway (per analyst notes).", "Street narrative supportive: Multiple Buys/Outperforms with price targets clustered around ~$60\u2013$70, implying upside vs ~53.84 pre-market.", "Competitive framing: Analysts cite favorable safety/durability and a less crowded landscape in NMIBC as supportive for adoption potential."]
than immediate."]
["Latest quarter: 2025/Q3.", "Revenue: $1.67M, up ~3774% YoY (growth off a very small base).", "Profitability: Net income -$43.81M and EPS -$0.57 (both improved YoY), consistent with a cash-burning clinical-stage profile.", "Gross margin: 5.34%, down ~94.66% YoY, indicating weak/volatile margin profile at this stage."]
["Recent trend: Predominantly bullish coverage with raised/initiated Buy/Outperform ratings and higher price targets into late 2025 and early 2026 (e.g., Truist raised to $66; Wedbush initiated at $70; RBC raised to $61).", "Wall Street pros: Strong efficacy/safety narrative for cretostimogene, physician buy-in implied by fast enrollment, large NMIBC market opportunity, and multiple upcoming clinical/regulatory milestones.", "Wall Street cons: Launch timing uncertainty (some models pushed to 2027), competitive questions remain, and execution/regulatory risks persist."]
